Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes.
He
Yan-Ling
YL
Arkansas Research, Little Rock, USA. yanling.he@novartis.com
Horowitz
Anne
A
Watson
Catherine E
CE
Foley
James E
JE
Sallas
William
W
Ligueros-Saylan
Monica
M
D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000704:Analysis of Variance; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000378:metabolism*; D002853:Chromatography, Liquid; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D018819:Dipeptidyl Peptidase 4 / Q000097:blood; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004311:Double-Blind Method; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000097:blood / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D011759:Pyrrolidines; D011863:Radioimmunoassay; D053719:Tandem Mass Spectrometry; D013997:Time Factors; D000077597:Vildagliptin
D001786:Blood Glucose; D002096:C-Peptide; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D009570:Nitriles; D011759:Pyrrolidines; D052216:Glucagon-Like Peptide 1; D018819:Dipeptidyl Peptidase 4; D000077597:Vildagliptin; D000218:Adamantane